Hoth's BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids.

 

NEW YORK, June 20, 2017  -- Spherix Incorporated (NASDAQ: SPEX) announced today that the Company has negotiated definitive terms to acquire a controlling interest in Hoth Therapeutics, a development stage biopharmaceutical company focused on the development of therapeutics for patients suffering from atopic dermatitis, such as eczema.  Closing of the deal with Hoth is subject to the completion and execution of customary closing documents, which the Company expects to be completed within 30 days or less.

The ARIEL3 study successfully achieved its primary endpoint of improved PFS by investigator review in all three primary efficacy analyses: tumor BRCA-mutant, HRD-positive and overall intent-to-treat populations

The ARIEL3 study successfully achieved the key secondary endpoint of improved PFS by blinded, independent central review (BICR) in each of the tumor BRCA-mutant, HRD-positive and overall intent-to-treat populations

The exploratory PFS endpoints were achieved by both investigator and independent review in the HRD-positive and HRD-negative subgroups of patients without a BRCA mutation

ARIEL3 patients with residual disease at study entry who were treated with rucaparib showed further reduction in tumor burden, including complete responses

The safety of rucaparib observed in ARIEL3 was highly consistent with the U.S. treatment label for Rubraca®

The Company plans to submit a supplemental NDA within the next four months

WATERTOWN, Mass., June 15, 2017 -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced data from its ongoing Phase 2 trial of SEL-212 (SVP-Rapamycin in combination with the uricase enzyme pegsiticase), which is being developed for patients with chronic severe gout.

 

Key observations and findings based upon the clinical data generated through June 12, 2017 from the 60 patients currently enrolled in this open-label, dose ranging Phase 2 trial include:

 

Mitigated anti-drug antibodies (ADAs) after repeat monthly administrations of SEL-212 – The prevention of ADAs in a dose-dependent manner resulted in durable control of serum uric acid (sUA) levels (defined as sUA <6 mg/dl). The clinical data demonstrate a correlation between the prevention of ADAs and the maintenance of pegsiticase activity and serum uric acid control.

MVT-2163 ImmunoPET Agent administered in combination with MVT-5873 was safe and well tolerated

Images demonstrate high accumulation of antibody on tumor with high correlation to CT

Results support the use of follow-on targeted radioimmunotherapy (MVT-1075) for the treatment of patients with pancreatic, lung and colon cancer

 

SAN DIEGO, June 14, 2017 -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, today reported results from its Phase 1 clinical trial of  its ImmunoPET imaging agent, MVT-2163, for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. Results from the Phase 1 clinical trial were presented in a poster session and podium talk at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Denver, COJune 10-14, 2017.